<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00861315</url>
  </required_header>
  <id_info>
    <org_study_id>DARTAGNAN</org_study_id>
    <nct_id>NCT00861315</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation</brief_title>
  <acronym>DARTAGNAN</acronym>
  <official_title>Phase II Study of High Dose Nebulized Amikacin in Patients With Pneumonia Undergoing Mechanical Ventilation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Pour La Promotion A Tours De La Reanimation Medicale</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Association Pour La Promotion A Tours De La Reanimation Medicale</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Inclusion of patients undergoing mechanical ventilation and presenting a pneumonia in order
      to determine serum pharmacokinetics of nebulized amikacin. The primary aim is to determine
      the dose of amikacin to be nebulized in order to observe amikacin serum concentrations close
      to but inferior to those observed after standart intravenous amikacin infusion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After inclusion, patients undergo intravenous infusion of 20 mg/Kg of amikacin with amikacin
      serum concentrations being monitored over the following 24 hours.

      Randomization occures after this first amikacin infusion. Patients are randomized to group
      nebulized amikacin or intravenous amikacin. The three next days of the study patients recieve
      nebulized amikacin (or nebulized placebo) during mechanical ventilation and a placebo
      infusion (amikacin infusion in case of placebo nebulization) using a air driven jet
      nebulizer. Amikacin serum concentrations are monitored over 24 hours after each nebulization.

      Patients are followed up during 10 days for safety and efficacy. The dose of amikacin to be
      nebulized is 60 mg/Kg for the first 6 patients (phase A), 80 mg/Kg for the next 6 patients
      (phase B) and 100 mg/Kg for the last 6 patients (phase C). Each phase is started after review
      of the results of the preceeding phase by an idependent safety and monitoring board.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determintion of nebulized amikacin dose (60 mg/Kg, 80 mg/Kg or 100 mg/Kg) which results in serum amikacin concentrations equal or below the serum amikacin concentrations measured after 20 mg/Kg intravenous amikacin infusion</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of clinical pulmonary infection score evolution between patients treated with nebulized amikacin and patients treated with intravenous amikacin</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of serum procalcitonin concentration evolution between patients treated with nebulized amikacin and patients treated with intravenous amikacin</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of c reactive protein evolution between patients treated with nebulized amikacin and patients treated with intravenous amikacin</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison duration of mechanical ventilation between patients treated with nebulized amikacin and patients treated with intravenous amikacin</measure>
    <time_frame>10 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Ventilator Associated Pneumonia</condition>
  <arm_group>
    <arm_group_label>Nebulized amikacin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive nebulized amikacin once a day during three days. Placebo is administered intravenousely</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenous amikacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nebulized amikacin</intervention_name>
    <description>Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)</description>
    <arm_group_label>Nebulized amikacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravenous amikacin</intervention_name>
    <description>20 mg/Kg amikacin are administred intravenousely once a day during three days.</description>
    <arm_group_label>Intravenous amikacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo nebulization</intervention_name>
    <description>0.9% saline solution is nebulized once a day during three days</description>
    <arm_group_label>Intravenous amikacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo infusion</intervention_name>
    <description>0.9% saline is administered intravenousely once a day during three days</description>
    <arm_group_label>Nebulized amikacin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients admitted to intensive care unit.

          -  Patients undergoing mechanical ventilation for more than 48H.

          -  Suspicion of ventilator associated pneumonia.

        Exclusion Criteria:

          -  Allergy to amikacin or any compound of the medication.

          -  Body mass index &gt; 30 kg/m2.

          -  Myasthenia gravis.

          -  Acute or chronic renal failure.

          -  Vestibulo-cochlear disease.

          -  Pregnancy.

          -  Brain death.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephan Ehrmann, MD</last_name>
    <phone>+33(0)671103302</phone>
    <email>stephanehrmann@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de réanimation médicale polyvalente. Hôpital Bretonneau CHRU</name>
      <address>
        <city>Tours</city>
        <state>Indre et Loire</state>
        <zip>F37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephan Ehrmann, MD</last_name>
      <phone>+33(0)671103302</phone>
      <email>stephanehrmann@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Stephan Ehrmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuelle Mercier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-François Dequin, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Denis Garot, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Annick Legras, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Perrotin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de réanimation médicale. Hôpital La Source. CH Orléans</name>
      <address>
        <city>Orléans</city>
        <state>Loiret</state>
        <zip>F45067</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry Boulain, MD</last_name>
      <phone>+33(0)238514446</phone>
      <email>thierry.boulain@chr-orleans.fr</email>
    </contact>
    <investigator>
      <last_name>Thierry Boulain, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2009</study_first_submitted>
  <study_first_submitted_qc>March 12, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2009</study_first_posted>
  <last_update_submitted>March 13, 2009</last_update_submitted>
  <last_update_submitted_qc>March 13, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 16, 2009</last_update_posted>
  <responsible_party>
    <name_title>Pr Dominique Perrotin</name_title>
    <organization>Association Pour La Promotion A Tours De La Reanimation Medicale</organization>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Nebulization</keyword>
  <keyword>Amikacin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pneumonia, Ventilator-Associated</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amikacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

